ImmuPharma Plc engages in the research, development, and commercialization of pharmaceutical products. It is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The firm's portfolio consists of four novel peptide therapy areas: autoimmunity, metabolism, cancer and anti-infectives. Its drug Lupuzor, is a potential treatment for the autoimmune chronic inflammatory disease lupus. The company was founded by Richard Warr and Dimitri F. Dimitriou in 1999 and is headquartered in London, the United Kingdom.
Sector:
Health Technology
Industry:
Pharmaceuticals Other
Employees:
N/A
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Immupharma Plc market cap is $28.34M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Immupharma Plc 52 week high is $0.085 as of November 21, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Immupharma Plc 52 week low is $0.085 as of November 21, 2026.
Immupharma Plc stock price today is $0.085.
Immupharma Plc stock price yesterday was $0.08.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Immupharma Plc's P/E ratio is -2.66.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Immupharma Plc P/B ratio is 9.8952.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Immupharma Plc 50-day moving average is $0.085.